PILA PHARMA AB (DE:5KC)

FRANKFURT:5KC

5KC

PILA PHARMA AB

RESEARCH TOOLSreports

Want to see DE:5KC full AI Analyst Report?

PILA PHARMA AB (5KC) Price & Analysis

0 Followers

5KC Stock Chart & Stats

€0.20

€0.09(20.09%)

At close: Jan 08 4:00 PM EST

€0.20

€0.09(20.09%)

Day’s Range― - ―

52-Week Range€0.09 - €0.41

Previous CloseN/A

Volume2.28K

Average Volume (3M)0.00

Market Cap

€7.51M

Enterprise Value€61.53M

Total Cash (Recent Filing)€1.08M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.48

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.42

Shares Outstanding45,682,120

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clean Balance Sheet (zero Debt)Zero reported debt in 2024–2025 reduces insolvency risk and lowers fixed financing costs, giving management flexibility to fund clinical programs via equity or partnerships. A debt-free structure supports operational resilience during multi-year R&D timelines.

Material Equity Increase Supporting SolvencyA meaningful rise in equity provides a larger capital buffer against ongoing R&D losses and extends runway without immediate debt. Higher shareholders' equity improves solvency metrics and strengthens negotiating leverage for licensing or partnership deals.

Focused Clinical Program In A Large Structural MarketConcentrated R&D on a TRPV1-targeting candidate for obesity and T2D aligns the company with enduring, high-demand metabolic disease markets. A clear, differentiated mechanism-focused pipeline can support durable partnering or out-licensing opportunities if clinical proof emerges.

Bears Say

Persistent Negative Cash FlowConsistent negative operating and free cash flow shows structural cash burn from R&D and operations. Unless cash burn narrows or new funding arrives, the company faces ongoing dilution risk and must prioritize financing or partnerships to sustain development over the next 2–6 months.

Widening Net Losses And Weak ProfitabilityA larger annual net loss indicates expanding operating deficits and limited margin scalability. Continued widening losses erode equity buffers and increase dependency on external capital, constraining strategic options and heightening execution risk for clinical programs.

No Commercial Revenue; Small, Volatile RevenuesAbsence of commercial product revenue and only minor, volatile receipts mean the company lacks organic cash generation. This structural revenue gap forces reliance on financing or deals to fund development, raising execution and dilution risks until commercialization or licensing occurs.

5KC FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was €0.09 and its highest was €0.41 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is €7.51M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 27, 2026 which is in 97 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -€0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.034.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -€0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.869%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in DE:5KC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.